|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005740,
umls-concept:C0006826,
umls-concept:C0008838,
umls-concept:C0013216,
umls-concept:C0015133,
umls-concept:C0029246,
umls-concept:C0034656,
umls-concept:C0035168,
umls-concept:C0042066,
umls-concept:C0086960,
umls-concept:C0087111,
umls-concept:C0239307,
umls-concept:C0740345,
umls-concept:C1511572,
umls-concept:C1521808,
umls-concept:C1551807,
umls-concept:C1556038,
umls-concept:C2603343
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2001-3-19
|
|
pubmed:abstractText |
To test the equivalence of three versus four cycles of bleomycin, etoposide, and cisplatin (BEP) and of the 5-day schedule versus 3 days per cycle in good-prognosis germ cell cancer.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1629-40
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:11250991-Adolescent,
pubmed-meshheading:11250991-Adult,
pubmed-meshheading:11250991-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11250991-Bleomycin,
pubmed-meshheading:11250991-Cisplatin,
pubmed-meshheading:11250991-Disease-Free Survival,
pubmed-meshheading:11250991-Drug Administration Schedule,
pubmed-meshheading:11250991-Etoposide,
pubmed-meshheading:11250991-Humans,
pubmed-meshheading:11250991-Male,
pubmed-meshheading:11250991-Middle Aged,
pubmed-meshheading:11250991-Neoplasms, Germ Cell and Embryonal,
pubmed-meshheading:11250991-Prognosis,
pubmed-meshheading:11250991-Quality of Life,
pubmed-meshheading:11250991-Seminoma,
pubmed-meshheading:11250991-Testicular Neoplasms,
pubmed-meshheading:11250991-Treatment Outcome
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council.
|
|
pubmed:affiliation |
Rotterdam Cancer Institute and University Hospital, Rotterdam, The Netherlands. wit@onch.azr.nl
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Multicenter Study
|
